A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder

The primary purpose of this study is to evaluate the efficacy of SAGE-217 plus an ADT in the treatment of major depressive disorder (MDD) compared to placebo plus an ADT.

Study Overview

• Status: Completed
• Conditions: Depressive Disorder, Major
• Intervention / Treatment: Drug: SAGE-217; Drug: Sertraline; Drug: Escitalopram; Drug: Citalopram; Drug: Duloxetine; Drug: Desvenlafaxine; Drug: Matching Placebo

Detailed Description

This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.

• Study Type: Interventional
• Enrollment (Actual): 440
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Dothan, Alabama, United States, 36303
      • Sage Investigational Site
  • Arizona
    • Phoenix, Arizona, United States, 85012
      • Sage Investigational Site
  • California
    • Anaheim, California, United States, 92805
      • Sage Investigational Site
    • Costa Mesa, California, United States, 92626
      • Sage Investigational Site
    • Glendale, California, United States, 91206
      • Sage Investigational Site
    • Irvine, California, United States, 92614
      • Sage Investigational Site
    • Los Alamitos, California, United States, 90720
      • Sage Investigational Site
    • Oceanside, California, United States, 92056
      • Sage Investigational Site
    • Orange, California, United States, 92868
      • Sage Investigational Site
    • Riverside, California, United States, 92503
      • Sage Investigational Site
    • San Diego, California, United States, 92103
      • Sage Investigational Site
    • Temecula, California, United States, 92591
      • Sage Investigational Site
  • Colorado
    • Colorado Springs, Colorado, United States, 80910
      • Sage Investigational Site
  • Connecticut
    • Cromwell, Connecticut, United States, 06416
      • Sage Investigational Site
    • Norwich, Connecticut, United States, 06360
      • Sage Investigational Site
  • Florida
    • Coral Springs, Florida, United States, 33067
      • Sage Investigational Site
    • Jacksonville, Florida, United States, 32256
      • Sage Investigational Site
    • Orlando, Florida, United States, 32807
      • Sage Investigational Site
    • Orlando, Florida, United States, 32801
      • Sage Investigational Site
    • Pensacola, Florida, United States, 32502
      • Sage Investigational Site
  • Georgia
    • Alpharetta, Georgia, United States, 30022
      • Sage Investigational Site
    • Atlanta, Georgia, United States, 30331
      • Sage Investigational Site
    • Marietta, Georgia, United States, 30060
      • Sage Investigational Site
    • Savannah, Georgia, United States, 31405
      • Sage Investigational Site
  • Illinois
    • Chicago, Illinois, United States, 60634
      • Sage Investigational Site
    • Chicago, Illinois, United States, 60640
      • Sage Investigational Site
  • Maryland
    • Towson, Maryland, United States, 21204
      • Sage Investigational Site
  • Massachusetts
    • Watertown, Massachusetts, United States, 02472
      • Sage Investigational Site
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Sage Investigational Site
  • Missouri
    • Saint Charles, Missouri, United States, 63304
      • Sage Investigational Site
  • Nebraska
    • Lincoln, Nebraska, United States, 68526
      • Sage Investigational Site
  • New Jersey
    • Cherry Hill, New Jersey, United States, 08002
      • Sage Investigational Site
    • Marlton, New Jersey, United States, 08053
      • Sage Investigational Site
    • Princeton, New Jersey, United States, 08540
      • Sage Investigational Site
  • New Mexico
    • Albuquerque, New Mexico, United States, 87109
      • Sage Investigational Site
  • New York
    • Brooklyn, New York, United States, 11229
      • Sage Investigational Site
    • Brooklyn, New York, United States, 11235
      • Sage Investigational Site
    • Mount Kisco, New York, United States, 10549
      • Sage Investigational Site
  • Ohio
    • Beachwood, Ohio, United States, 44122
      • Sage Investigational Site
    • Cincinnati, Ohio, United States, 45212
      • Sage Investigational Site
    • Cincinnati, Ohio, United States, 45215
      • Sage Investigational Site
    • Cincinnati, Ohio, United States, 45219
      • Sage Investigational Site
    • North Canton, Ohio, United States, 44720
      • Sage Investigational Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73112
      • Sage Investigational Site
  • Pennsylvania
    • Plymouth Meeting, Pennsylvania, United States, 19462
      • Sage Investigational Site
  • Texas
    • Austin, Texas, United States, 78759
      • Sage Investigational Site
    • Dallas, Texas, United States, 75231
      • Sage Investigational Site
    • Houston, Texas, United States, 77030
      • Sage Investigational Site
    • Houston, Texas, United States, 77081
      • Sage Investigational Site
    • Wichita Falls, Texas, United States, 76309
      • Sage Investigational Site
  • Washington
    • Bellevue, Washington, United States, 98007
      • Sage Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 62 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of MDD as diagnosed by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Clinical Trials Version (SCID-5-CT), with symptoms that have been present for at least a 4-week period
• 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score of ≥24 at Screening and Day 1
• Participant in good physical health and has no clinically significant findings, as determined by the investigator, on physical examination, 12-lead electrocardiogram (ECG), or clinical laboratory tests
• Participant is willing, able, and eligible to take at least 1 of the 5 ADTs specified in the protocol (an eligible ADT is an ADT that has not been taken during the current depressive episode and for which the participant has no contraindications; further, a participant is not eligible for citalopram if escitalopram has been taken during the current depressive episode, and vice versa)

Exclusion Criteria:

• Has attempted suicide associated with the current episode of MDD
• Participant had onset of the current depressive episode during pregnancy or 4 weeks postpartum, or the participant has presented for screening during the 6-month postpartum period
• Participant has treatment-resistant depression
• History of bipolar disorder, schizophrenia, and/or schizoaffective disorder
• Known allergy to SAGE-217, allopregnanolone, or related compounds
• Has taken antidepressants within 30 days prior to Day 1, and/or has taken fluoxetine within 60 days prior to Day 1

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Placebo + Assigned ADT; Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.	Drug: Sertraline; Oral tablets; Drug: Escitalopram; Oral tablets; Drug: Citalopram; Oral tablets; Drug: Duloxetine; Oral capsules; Drug: Desvenlafaxine; Oral tablets; Drug: Matching Placebo; Oral capsules
Experimental: SAGE-217 + Assigned ADT; Participants received SAGE-217, 50 milligrams (mg), orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.	Drug: SAGE-217; Oral capsules; Drug: Sertraline; Oral tablets; Drug: Escitalopram; Oral tablets; Drug: Citalopram; Oral tablets; Drug: Duloxetine; Oral capsules; Drug: Desvenlafaxine; Oral tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in the HAMD-17 Total Score at Day 3	The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. Least Squares (LS) mean was estimated using mixed effects model for repeated measures (MMRM) analysis.	Baseline, Day 3

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in the HAMD-17 Total Score Over the Double-Blind Treatment Period	The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis. The data reported is summary of data collected and analyzed during double-blind treatment period at Baseline, Day 3, Day 8, Day 12, and Day 15 using equal weights for the scheduled visits.	Baseline through Day 15
Change From Baseline in the HAMD-17 Total Score at Days 15 and 42	The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis. The missing values were imputed for the analysis.	Baseline, Days 15 and 42
Change From Baseline in the HAMD-17 Total Score Around End of Blinded Treatment	The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. End of blinded treatment was defined as the average of change from baseline values of Days 12, 15 and 18. LS mean was estimated using MMRM analysis.	Baseline, End of blinded treatment assessment (i.e., average of Days 12, 15 , and 18)
Percentage of Participants With HAMD-17 Response at Day 15 and Day 42	HAM-D response was defined as having a 50% or greater reduction from baseline in HAM-D total score. The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. Percentages were rounded off to the first decimal point.	At Days 15 and 42
Percentage of Participants With HAMD-17 Remission at Day 15 and Day 42	HAM-D remission was defined as having a HAM-D total score of ≤7. The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. Percentages were rounded off to the first decimal point.	Days 15 and 42
Change From Baseline in CGI-S Score at Day 15	The CGI-S uses a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. Considering total clinical experience, the investigator rated the participant on severity of mental illness at the time of rating as: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = extremely ill. A higher score indicated extreme illness. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.	Baseline and Day 15
Percentage of Participants With CGI-I Response, at Day 3 and Day 15	CGI-I response was defined as having a CGI-I score of "very much improved" or "much improved." The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to IP. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. By definition, all CGI-I assessments are evaluated against baseline conditions. Higher scores indicated worse condition. Percentages were rounded off to the first decimal point.	Days 3 and 15
Change From Baseline in MADRS Total Score at Day 15	The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores. Each item yields a score of 0 (no symptoms) to 6 (symptoms of maximum severity). The total MADRS score (sum of all individual items) ranges from 0 (symptoms absent) to 60 (severe depression). Higher MADRS scores indicated more severe depression. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.	Baseline and Day 15
Percentage of Participants With MADRS Response at Day 15	MADRS response was defined as having a 50% or greater reduction from baseline in MADRS total score. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores. Each item yields a score of 0 (no symptoms) to 6 (symptoms of maximum severity). The total MADRS score (sum of all individual items) ranges from 0 (symptoms absent) to 60 (severe depression). Higher MADRS scores indicated more severe depression. Percentages were rounded off to the first decimal point.	Day 15
Percentage of Participants With MADRS Remission at Day 15	MADRS remission was defined as having a MADRS total score of ≤10. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores. Each item yields a score of 0 (no symptoms) to 6 (symptoms of maximum severity). The total MADRS score (sum of all individual items) ranges from 0 (symptoms absent) to 60 (severe depression). Higher MADRS scores indicated more severe depression. Percentages were rounded off to the first decimal point.	Day 15
Change From Baseline in HAM-A Total Score at Day 15	Each of the 14 items in the HAM-A was defined by a series of symptoms, and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints). The HAM-A total score was calculated as sum of the 14 individual item scores, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The total score (sum of all individual items) range from 0 to 56, where <17 indicated mild severity, 18 to 24 indicated mild to moderate severity, and 25 to 30 indicated moderate to severe severity. Higher scores indicated more severe disease. Negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.	Baseline, Day 15
Time to First HAMD-17 Response	HAM-D response was defined as having a 50% or greater reduction from baseline in HAM-D total score. The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. Time (in days) from first dose of study drug to time of first HAMD response was reported in this outcome measure.	From first dose of study drug up to first HAMD-17 response (up to approximately 65 days)
Change From Baseline in Depressive Symptoms at Day 15, as Assessed by PHQ-9	The PHQ-9 is a participant-rated depressive symptom severity scale. The PHQ-9 total score is calculated as the sum of the 9 individual item scores. For individual items, scoring is based on responses to specific questions, as follows: 0 = not at all; 1 = several days; 2 = more than half the days; and 3 = nearly every day. The PHQ-9 possible total score range is 0 to 27, with higher scores reflecting greater depressive symptoms, and is categorized as follows: 0 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderately severe depression, and 20 to 27 = severe depression. Negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.	Baseline and Day 15
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)	An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.	Up to approximately 58 weeks
Percentage of Participants With TEAEs, Graded by Severity	An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study. The severity was graded as mild, moderate and severe.	Up to approximately 58 weeks

Collaborators and Investigators

• Sponsor: Biogen

Study record dates

Study Major Dates

• Study Start (Actual): November 9, 2020
• Primary Completion (Actual): October 25, 2021
• Study Completion (Actual): December 22, 2021

Study Registration Dates

• First Submitted: July 15, 2020
• First Submitted That Met QC Criteria: July 15, 2020
• First Posted (Actual): July 17, 2020

Study Record Updates

• Last Update Posted (Actual): December 22, 2023
• Last Update Submitted That Met QC Criteria: December 20, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: MDD; Major Depressive Disorder; SAGE-217
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Depression; Depressive Disorder; Depressive Disorder, Major; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Psychotropic Drugs; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Serotonin Agents; Antidepressive Agents; Dopamine Agents; Antidepressive Agents, Second-Generation; Serotonin and Noradrenaline Reuptake Inhibitors; Selective Serotonin Reuptake Inhibitors; Sertraline; Duloxetine Hydrochloride; Citalopram; Desvenlafaxine Succinate; Escitalopram
• Other Study ID Numbers: 217-MDD-305

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No